BioStock published an article on 29 April 2020 about Aptahem, which can be read in full below. Aptahem, whose primary drug candidate Apta-1 is being developed as an acute treatment for sepsis, recently announced that it is expanding its team...
Read MoreAptahem today announced that the company is expanding its team with Suzanne Kilany as Clinical Research Director for the next step in the development of the company’s lead drug candidate, Apta-1. Suzanne will primarily lead and coordinate the planning...
Read MoreBioStock published an article on 2 April 2020 about Aptahem, which can be read in full below. Aptahem has recently published an abstract containing data on its lead drug candidate Apta-1, which is being developed as an emergency treatment for...
Read More